Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.57
IDXX's Cash to Debt is ranked higher than
55% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. IDXX: 0.57 )
IDXX' s 10-Year Cash to Debt Range
Min: 0.41   Max: No Debt
Current: 0.57

Equity to Asset 0.35
IDXX's Equity to Asset is ranked higher than
53% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. IDXX: 0.35 )
IDXX' s 10-Year Equity to Asset Range
Min: 0.35   Max: 0.9
Current: 0.35

0.35
0.9
Interest Coverage 49.53
IDXX's Interest Coverage is ranked higher than
59% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 116.56 vs. IDXX: 49.53 )
IDXX' s 10-Year Interest Coverage Range
Min: 32.59   Max: 9999.99
Current: 49.53

32.59
9999.99
F-Score: 6
Z-Score: 8.07
M-Score: -2.77
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 19.41
IDXX's Operating margin (%) is ranked higher than
95% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. IDXX: 19.41 )
IDXX' s 10-Year Operating margin (%) Range
Min: -1.67   Max: 20.3
Current: 19.41

-1.67
20.3
Net-margin (%) 13.36
IDXX's Net-margin (%) is ranked higher than
92% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.31 vs. IDXX: 13.36 )
IDXX' s 10-Year Net-margin (%) Range
Min: -8.02   Max: 14.26
Current: 13.36

-8.02
14.26
ROE (%) 37.53
IDXX's ROE (%) is ranked higher than
98% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.65 vs. IDXX: 37.53 )
IDXX' s 10-Year ROE (%) Range
Min: -6.75   Max: 32.54
Current: 37.53

-6.75
32.54
ROA (%) 15.71
IDXX's ROA (%) is ranked higher than
95% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.89 vs. IDXX: 15.71 )
IDXX' s 10-Year ROA (%) Range
Min: -5.62   Max: 17.84
Current: 15.71

-5.62
17.84
ROC (Joel Greenblatt) (%) 61.24
IDXX's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.66 vs. IDXX: 61.24 )
IDXX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2.93   Max: 96.66
Current: 61.24

-2.93
96.66
Revenue Growth (%) 11.20
IDXX's Revenue Growth (%) is ranked higher than
85% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.80 vs. IDXX: 11.20 )
IDXX' s 10-Year Revenue Growth (%) Range
Min: 8.4   Max: 23.1
Current: 11.2

8.4
23.1
EBITDA Growth (%) 12.50
IDXX's EBITDA Growth (%) is ranked higher than
84% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. IDXX: 12.50 )
IDXX' s 10-Year EBITDA Growth (%) Range
Min: -31.8   Max: 98.1
Current: 12.5

-31.8
98.1
EPS Growth (%) 13.70
IDXX's EPS Growth (%) is ranked higher than
84% of the 131 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. IDXX: 13.70 )
IDXX' s 10-Year EPS Growth (%) Range
Min: -0.8   Max: 26.4
Current: 13.7

-0.8
26.4
» IDXX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

IDXX Guru Trades in Q3 2013

Steven Cohen 7,100 sh (New)
Ron Baron 3,688,385 sh (+2.88%)
Jean-Marie Eveillard 4,000 sh (unchged)
Paul Tudor Jones Sold Out
Ruane Cunniff 5,344,172 sh (-0.14%)
Chris Davis 168,443 sh (-6.31%)
Chuck Royce 1,493,311 sh (-8.66%)
Jeremy Grantham 39,890 sh (-14.56%)
Joel Greenblatt 2,953 sh (-23.04%)
Jim Simons 118,700 sh (-65.34%)
» More
Q4 2013

IDXX Guru Trades in Q4 2013

Bill Frels 4,999 sh (New)
Paul Tudor Jones 2,407 sh (New)
Steven Cohen 8,891 sh (+25.23%)
Ron Baron 3,727,807 sh (+1.07%)
Chris Davis 169,541 sh (+0.65%)
Chuck Royce 1,495,311 sh (+0.13%)
Jean-Marie Eveillard 4,000 sh (unchged)
Ruane Cunniff 5,271,088 sh (-1.37%)
Joel Greenblatt 2,834 sh (-4.03%)
Jeremy Grantham 37,423 sh (-6.18%)
Jim Simons 73,552 sh (-38.04%)
» More
Q1 2014

IDXX Guru Trades in Q1 2014

Ray Dalio 2,301 sh (New)
Steven Cohen 39,307 sh (+342.1%)
Chris Davis 179,579 sh (+5.92%)
Ron Baron 3,729,920 sh (+0.06%)
Bill Frels 4,999 sh (unchged)
Jean-Marie Eveillard 4,000 sh (unchged)
Paul Tudor Jones Sold Out
Ruane Cunniff 5,252,649 sh (-0.35%)
Joel Greenblatt 2,818 sh (-0.56%)
Chuck Royce 1,203,911 sh (-19.49%)
Jim Simons 58,900 sh (-19.92%)
Jeremy Grantham 26,700 sh (-28.65%)
» More
Q2 2014

IDXX Guru Trades in Q2 2014

Paul Tudor Jones 1,600 sh (New)
RS Investment Management 168,010 sh (New)
Jim Simons 151,400 sh (+157.05%)
Chris Davis 185,256 sh (+3.16%)
Chuck Royce 1,203,911 sh (unchged)
Joel Greenblatt Sold Out
Jean-Marie Eveillard Sold Out
Ray Dalio Sold Out
Ruane Cunniff 5,238,390 sh (-0.27%)
Ron Baron 3,692,912 sh (-0.99%)
Jeremy Grantham 25,600 sh (-4.12%)
Bill Frels 2,999 sh (-40.01%)
» More
» Details

Insider Trades

Latest Guru Trades with IDXX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 Sold Out 0.01%$117.5 - $134.88 $ 120.58-5%0
Jean-Marie Eveillard 2014-06-30 Sold Out $117.5 - $134.88 $ 120.58-5%0
Ray Dalio 2014-06-30 Sold Out $117.5 - $134.88 $ 120.58-5%0
Ray Dalio 2014-03-31 New Buy$105.03 - $128.26 $ 120.582%2301
Joel Greenblatt 2013-09-30 Reduce -23.04%$88.73 - $99.19 $ 120.5825%2953
Ron Baron 2013-06-30 Add 21.04%0.3%$82.44 - $91 $ 120.5838%3584998
Joel Greenblatt 2013-06-30 New Buy0.02%$82.44 - $91 $ 120.5838%3837
Meridian Funds 2012-09-30 Reduce -23.09%0.42%$87.21 - $100 $ 120.5828%427500
Meridian Funds 2012-06-30 Add 7.33%0.12%$82.04 - $95.92 $ 120.5838%555820
John Hussman 2012-03-31 Sold Out 0.06%$78.98 - $89.03 $ 120.5851%0
John Hussman 2011-09-30 Reduce -69.33%0.13%$71.13 - $86.97 $ 120.5856%46000
Ray Dalio 2011-09-30 Sold Out 0.05%$71.13 - $86.97 $ 120.5856%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Idexx Laboratories

Baron Funds Comments on IDEXX Laboratories - May 02, 2014

Shares of IDEXX Laboratories, Inc. (IDXX), a leader in veterinary diagnostics, rose on evidence of improving organic growth and excitement around its launch of CatalystOne, a new diagnostic platform. During its most recent quarter, IDEXX's organic revenue growth improved from mid-single digits to 11%, helped by strong instrument sales and accelerating volumes for the associated consumables. We believe that recent innovations in its diagnostic products, data management capabilities, and its go-to-market strategy have positioned IDEXX to continue recent market share gains and to significantly accelerate its revenue growth.



From Baron Funds' first quarter 2014 commentary.





Check out Ron Baron latest stock trades

Baron Funds Comments on IDEXX Laboratories - Feb 06, 2013

Shares of IDEXX Laboratories, Inc. (IDXX), a leading supplier of diagnostic products and tools to the veterinary market, retreated from all-time highs after the company modestly reduced its 2012 revenue expectations. Nevertheless, management provided better than expected revenue guidance for 2013. We remain excited about the company's significant long-term opportunity in veterinary diagnostics and testing. We believe the confluence of the company's emerging new technology platform, its escalating pace of new product introduction, secular trends toward wellness testing for pets, and a modest economic tailwind driving more traffic to veterinarians will lead to accelerating growth in 2013 and beyond.

From Baron Funds' fourth quarter letter.


Check out Ron Baron latest stock trades

Top Ranked Articles about Idexx Laboratories

Baron Funds Comments on IDEXX Laboratories
Shares of IDEXX Laboratories, Inc. (IDXX), a leader in veterinary diagnostics, rose on evidence of improving organic growth and excitement around its launch of CatalystOne, a new diagnostic platform. During its most recent quarter, IDEXX's organic revenue growth improved from mid-single digits to 11%, helped by strong instrument sales and accelerating volumes for the associated consumables. We believe that recent innovations in its diagnostic products, data management capabilities, and its go-to-market strategy have positioned IDEXX to continue recent market share gains and to significantly accelerate its revenue growth. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 32.90
IDXX's P/E(ttm) is ranked higher than
82% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. IDXX: 32.90 )
IDXX' s 10-Year P/E(ttm) Range
Min: 15.21   Max: 44.22
Current: 32.9

15.21
44.22
P/B 13.66
IDXX's P/B is ranked higher than
52% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.80 vs. IDXX: 13.66 )
IDXX' s 10-Year P/B Range
Min: 3.73   Max: 15.45
Current: 13.66

3.73
15.45
P/S 4.39
IDXX's P/S is ranked higher than
65% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.86 vs. IDXX: 4.39 )
IDXX' s 10-Year P/S Range
Min: 1.75   Max: 4.97
Current: 4.39

1.75
4.97
PFCF 31.48
IDXX's PFCF is ranked higher than
87% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. IDXX: 31.48 )
IDXX' s 10-Year PFCF Range
Min: 12.97   Max: 240
Current: 31.48

12.97
240
EV-to-EBIT 22.27
IDXX's EV-to-EBIT is ranked higher than
81% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. IDXX: 22.27 )
IDXX' s 10-Year EV-to-EBIT Range
Min: 10.7   Max: 31.8
Current: 22.27

10.7
31.8
PEG 2.49
IDXX's PEG is ranked higher than
92% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. IDXX: 2.49 )
IDXX' s 10-Year PEG Range
Min: 0.77   Max: 2.82
Current: 2.49

0.77
2.82
Shiller P/E 41.21
IDXX's Shiller P/E is ranked higher than
89% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. IDXX: 41.21 )
IDXX' s 10-Year Shiller P/E Range
Min: 20.68   Max: 67.08
Current: 41.21

20.68
67.08
Current Ratio 1.17
IDXX's Current Ratio is ranked higher than
51% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. IDXX: 1.17 )
IDXX' s 10-Year Current Ratio Range
Min: 1.05   Max: 8.34
Current: 1.17

1.05
8.34
Quick Ratio 0.93
IDXX's Quick Ratio is ranked higher than
51% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. IDXX: 0.93 )
IDXX' s 10-Year Quick Ratio Range
Min: 0.78   Max: 7.55
Current: 0.93

0.78
7.55

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 28.71
IDXX's Price/Tangible Book is ranked higher than
56% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.91 vs. IDXX: 28.71 )
IDXX' s 10-Year Price/Tangible Book Range
Min: 1.62   Max: 31.84
Current: 28.71

1.62
31.84
Price/DCF (Projected) 2.47
IDXX's Price/DCF (Projected) is ranked higher than
82% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. IDXX: 2.47 )
IDXX' s 10-Year Price/DCF (Projected) Range
Min: 1.49   Max: 3.99
Current: 2.47

1.49
3.99
Price/Median PS Value 1.16
IDXX's Price/Median PS Value is ranked higher than
71% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.27 vs. IDXX: 1.16 )
IDXX' s 10-Year Price/Median PS Value Range
Min: 0.47   Max: 2.28
Current: 1.16

0.47
2.28
Price/Peter Lynch Fair Value 2.49
IDXX's Price/Peter Lynch Fair Value is ranked higher than
92% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. IDXX: 2.49 )
IDXX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.9   Max: 4.84
Current: 2.49

0.9
4.84
Price/Graham Number 6.39
IDXX's Price/Graham Number is ranked higher than
76% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. IDXX: 6.39 )
IDXX' s 10-Year Price/Graham Number Range
Min: 1.3   Max: 7.09
Current: 6.39

1.3
7.09
Earnings Yield (Greenblatt) 4.50
IDXX's Earnings Yield (Greenblatt) is ranked higher than
67% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.70 vs. IDXX: 4.50 )
IDXX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 9.4
Current: 4.5

3.1
9.4
Forward Rate of Return (Yacktman) 14.93
IDXX's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. IDXX: 14.93 )
IDXX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 14.5   Max: 22.9
Current: 14.93

14.5
22.9

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:IX1.Germany
Idexx Laboratories, a Delaware corporation, was incorporated in 1983. The Company develop, manufacture and distribute products and provide services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market. Its product and services includes point-of-care veterinary diagnostic products, veterinary reference laboratory diagnostic and consulting services, practice management systems and services and digital radiography systems, as well as biological materials testing and laboratory diagnostic instruments and services, among others. Its operations are segmented into three namely - CAG, Water, LPD, and Other. CAG develops, designs, manufactures, and distributes products and performs services for veterinarians and the bioresearch market, primarily related to diagnostics and information management. Water segment develops, designs, manufactures and distributes a range of products used in the detection of various microbiological parameters in water. LPD segment develops, designs, manufactures and distributes diagnostic tests and related instrumentation that are used to detect a wide range of diseases and to monitor health status in livestock and poultry. The Other segment is comprised of Dairy and OPTI Medical operating segments and a product line and out-licensing arrangements remaining from pharmaceutical business. Dairy segment develops, designs, manufactures and distributes products to detect contaminants in milk. OPTI Medical develops, designs, manufactures, and distributes point-of-care electrolyte and blood gas analyzers and related consumable products for the human medical diagnostics market. Further, OPTI Medical manufactures VetStat Electrolyte and Blood Gas Analyzer and electrolyte consumables used with its Catalyst Dx analyzer.
» More Articles for IDXX

Headlines

Articles On GuruFocus.com
Baron Funds Comments on IDEXX Laboratories May 02 2014 
IDEXX Laboratories, Inc. - Value Alert May 23 2013 
Weekly Top Insider Sells Feb 11 2013 
Weekly CFO Sells Highlight: FB, FSL, IVZ, IDXX, PFMT, CTXS Feb 10 2013 
Baron Funds Comments on IDEXX Laboratories Feb 06 2013 
Baron Funds Comments on IDEXX Laboratories Aug 23 2012 
comment on IDXX Aug 13 2012 
comment on IDXX Jun 30 2012 
4 Highly Predictable Small/Mid-Caps with ROC Over 15% Mar 31 2012 
Comment for Companies Ranked by Business Predictability Jan 12 2012 

More From Other Websites
IDEXX Laboratories to Release 2014 Third Quarter Financial Results Oct 14 2014
IDEXX Laboratories to Release 2014 Third Quarter Financial Results Oct 14 2014
IDEXX Laboratories Poised on Strong CAG Growth Globally Oct 07 2014
IDEXX Announces Several Milestones in its US All-Direct CAG Distribution Strategy Oct 01 2014
IDEXX Laboratories Names Jacqueline L. Studer Corporate Vice President and General Counsel Sep 18 2014
IDEXX LABORATORIES INC /DE Files SEC form 8-K, Creation of a Direct Financial Obligation or an... Sep 10 2014
Howard Zauberman, the President and CEO of Vision-Sciences, Inc. (VSCI), Interviews with The Wall... Aug 08 2014
IDEXX LABORATORIES INC /DE Financials Aug 01 2014
IDEXX Laboratories to Host 2014 Analyst Day Jul 31 2014
IDEXX Laboratories Tops Q2 Earnings & Revenue Estimates Jul 29 2014
IDEXX LABORATORIES INC /DE Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation... Jul 25 2014
Idexx Laboratories (IDXX) Is Today's Water-Logged And Getting Wetter Stock Jul 25 2014
Q2 2014 Idexx Laboratories Earnings Release - Before Market Open Jul 25 2014
IDEXX sees FY15 organic revenue growth of 9%-10% Jul 25 2014
IDEXX says all-direct distribution model to capture $50M-$55M in additional reve Jul 25 2014
IDEXX plans to move from hybrid to all-direct product distribution model in 2015 Jul 25 2014
IDEXX Laboratories Announces Second Quarter Results Jul 25 2014
Should You Sell IDEXX Laboratories (IDXX) Before Earnings? Jul 24 2014
Intuitive Surgical Bottom Seen As Procedures Rise Jul 23 2014
IDEXX Poised on Strong Global Companion Animal Group Growth (revised) Jul 18 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK